Stay updated with breaking news from Nagla abdel karim. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more. ....